Dear All (wonkish alert … lots of details here … take your time and absorb it all!), I’ve written several times about the concept of DTR, or Difficult-to-Treat resistance, that was proposed in 2018 by Kadri et al. Today we will consider an important update from Kadri and colleagues in which the idea of DTR
Dear All, We’ve previously discussed the availability of large surveillance datasets from the Vivli AMR Register. In particular, you should review Patricia Bradford’s summary of ways to use these data in the 20 Oct 2024 newsletter entitled “Vivli: Access to Industry’s Susceptibility Surveillance data.” Vivli have now announced their 2025 Vivli AMR Surveillance Data Challenge. This particular challenge is
Dear All, No one is safe until we’re all safe! In the 7 April 2025 newsletter on antibiotic access (“UNSLAP: You reach for the antibiotic … and it’s not there!”), Louise Norton-Smith and I concluded that we need to work to address all the elements of the long and delicate supply chain from manufacturing to local
Dear All, The Advisory Committee on Immunization Practices (ACIP) is scheduled to meet 26-28 Feb 2025 (see links below my signature for deeper background on ACIP and how it advises on vaccine use). At least as of today, the ACIP meeting is scheduled to occur as planned: it has a full agenda that covers meningococcal vaccine, influenza
Dear All, At BEAM’s AMR Conference in Basel, Team CARB-X have today announced their 2025 funding round. Key points: Two themes: (i) Direct-acting small molecule therapeutics for Gram-negatives (same as in 2024) and (ii) diagnostics for typhoid fever in low-resource settings. 23 Mar 2025 newsletter update: The TPPs for both themes have been released: Small
Dear All, Two quick updates this evening. First, you will recall that CARB-X have announced their initial 2025 funding round (26 Feb 2025 newsletter), with a call for applications for funding of work on (i) small molecules for Gram-negative infection and (ii) diagnostics for typhoid. In support of these calls, TPPs (target product profiles) for both
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact
Dear All, As you know, WHO have been steadfastly producing both priority pathogens lists (PPLs) and pipeline reviews. My current summaries of both are found at https://amr.solutions/pathogens-and-pipelines/. WHO began this process in 2017 with an initial focus antibacterial agents. To date, they have released multiple antibacterial pipeline reviews (2017, 2018, 2019, 2020, 2021 and 2023, see
24 Mar 2025 update: The call is live! It’s entitled “Development of a Rapid Point-of-care Antimicrobial Susceptibility Testing Diagnostic Medical Device (HADEA/2025/CPN/0006).” To apply, you must submit a request to participate by 12 May 2025; selected candidates who met the eligibility criteria will be able to submit a full technical tender. See the 24 Mar 2025 newsletter for a
Dear All, I wrote in the 19 Feb 2025 newsletter about HERA’s 13m EUR call for rapid point-of-care susceptibility devices. The call is now live! Title: Development of a Rapid Point-of-care Antimicrobial Susceptibility Testing Diagnostic Medical Device (HADEA/2025/CPN/0006) Funding and Tenders portal link: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/tender-details/2e5c607e-6e55-4268-b99a-730c5db350b7-CN “This call for tenders aims to speed up the development of an in